Boston Scientific, which originally held a 28% stake, will acquire gynecological surgery product technology developer IoGyn, with their products to be integrated.
Medical device manufacturer Boston Scientific has agreed to acquire portfolio company IoGyn, the US-based developer of a system for the removal of fibroids and polyps, for $65m.
Boston Scientific held a 28% stake in IoGyn, together with about $8m in notes receivable. The $65m will be used to acquire the remaining equity and pay off outstanding debt.
IoGyn previously raised $5m in August 2012, according to an SEC filing, though the company has not disclosed the investors in that round.…
